Orawee Chinthakanan

Dr. Orawee Chinthakanan


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2015 in Journal of Minimally Invasive Gynecology
Verified
Journal Article
Closed access
JMJohn R. Miklos
John R. Miklos
RMRobert D. Moore
Robert D. Moore
OCOrawee Chinthakanan
Orawee Chinthakanan

3 November 2023 in Medicina
Verified
Journal Article
Open access
PDF file
OCOrawee Chinthakanan
Orawee Chinthakanan
PSPokket Sirisreetreerux
Pokket Sirisreetreerux
ASApisith Saraluck
Apisith Saraluck
Background and Objectives: Vesicovaginal fistulas (VVFs) are an abnormal communication between the vagina and bladder and the most common type of acquired genital fistulas. This review will address the prevalence, impact, and management challenges of VVFs. Materials and Methods: Epidemiologic studies examining VVFs are considered. In addition, publications addressing the treatment of VVFs are reviewed. Results: VVFs in developing countries are often caused by obstructed labor, while most VVFs in developed countries have iatrogenic causes, such as hysterectomy, radiation therapy, and infection. The reported prevalence of VVFs is approximately 1 in 1000 post-hysterectomy patients and 1 in 1000 deliveries. VVFs affect every aspect of quality of life, including physical, mental, social, and sexual aspects. Prevention of VVFs is essential. Early diagnosis is necessary to reduce morbidity. Nutrition, infection control, and malignancy detection are important considerations during evaluation and treatment. Conservative and surgical treatment options are available; however, these approaches should be customized to the individual patient. The success rate of combined conservative and surgical treatments exceeds 90%. Conclusions: VVFs are considered debilitating and devastating. However, they are preventable and treatable; key factors include the avoidance of prolonged labor, careful performance of gynecologic surgery, and early detection.

18 December 2023 in Neurourology and Urodynamics
Verified
Journal Article
Open access
ASApisith Saraluck
Apisith Saraluck
OCOrawee Chinthakanan
Orawee Chinthakanan
AKAthasit Kijmanawat
Athasit Kijmanawat
KAKomkrit Aimjirakul
Komkrit Aimjirakul
RWRujira Wattanayingcharoenchai
Rujira Wattanayingcharoenchai
JMJittima Manonai
Jittima Manonai
Importance: Autologous platelet‐rich plasma (A‐PRP) injection is a novel intervention for stress urinary incontinence (SUI) in women. However, no Phase II clinical trial has compared the outcomes of A‐PRP injection combined with pelvic floor muscle training (PFMT) with those of PFMT alone in these women.Objective: The primary aim was to compare the efficacy of A‐PRP + PFMT versus PFMT alone in women with SUI. The secondary aim was to determine any adverse effects of A‐PRP injection.Design: Randomized clinical trial, single‐blind assessment.Setting: Urogynecology clinic at a tertiary medical center.Participants: Women with previously untreated SUI. Women in whom there was any suspicion of urgency, those with an Overactive Bladder Symptoms Score of ≥1, and those with obesity, pelvic organ prolapse, thrombocytopenia, or coagulopathy were excluded.Interventions: Two injections of A‐PRP were administered with a 1‐month interval between injections in the A‐PRP injection + PFMT group. Both groups received PFMT.Main Outcomes and Measures: The primary outcome was determined using the 1‐h pad weight test (PWT). Secondary outcomes were measured using the Incontinence Quality of Life Questionnaire, item 11 on the International Consultation on Incontinence Questionnaire‐Female Lower Urinary Tract Symptoms questionnaire, Patient Global Impression of Improvement, and the percentage subjective improvement score.Results: Data for 60 study participants were available for analysis (A‐PRP + PFMT group, n = 31; PFMT group, n = 29). The 1‐h PWT decreased significantly in the A‐PRP + PFMT group but only slightly in the PFMT group at the 5‐month follow‐up. There was a statistically significant between‐group difference in the 1‐h pad weight of about 8 g in favor of the A‐PRP + PFMT group. A statistically significant difference in symptoms of SUI measured by the questionnaires was found between the A‐PRP + PFMT group and the PFMT group at the 2‐ and 5‐month follow‐up assessments. There were no reports of adverse events following injection of A‐PRP.Conclusions and Relevance: A‐PRP + PFMT could be a treatment option for women with SUI. Large Phase III randomized controlled trials are required to confirm our findings.

30 November 2017 in Reproductive Health Matters
Verified
Journal Article
Open access
ETEllen Tousaw
Ellen Tousaw
RLRa Khin La
Ra Khin La
GAGrady Arnott
Grady Arnott
OCOrawee Chinthakanan
Orawee Chinthakanan
AFAngel M. Foster
Angel M. Foster
For displaced and migrant women in northern Thailand, access to health care is often limited, unwanted pregnancy is common, and unsafe abortion is a major contributor to maternal death and disability. Based on a pilot project and situational analysis research, in 2015 a multinational team introduced the Safe Abortion Referral Programme (SARP) in Chiang Mai, Thailand, to reduce the socio-linguistic, economic, documentation, and transportation barriers women from Burma face in accessing safe and legal abortion care in Thailand. Our qualitative study documented the experiences of women with unwanted pregnancies who accessed the SARP in order to inform programme improvement and expansion. We conducted 22 in-depth, in-person interviews and analysed them for content and themes using deductive and inductive techniques. Women were overwhelmingly positive about their experiences using the SARP. They reported lack of costs, friendly programme staff, accompaniment to and interpretation at the providing facility, and safety of services as key features. Financial and legal circumstances shaped access to the programme and women learned about the SARP through word-of-mouth and community workshops. After accessing the SARP and receiving support, women became community advocates for reproductive health. Efforts to expand the programme and raise awareness in migrant communities appear warranted. Our findings suggest that referral programmes for safe and legal abortion can be successful in settings with large displaced and migrant populations. Identifying ways to work within legal constraints to expand access to safe services has the potential to reduce harm from unsafe abortion even in humanitarian settings.

27 January 2018 in International Urogynecology Journal
Verified
Journal Article
Closed access
PDF file
APAlin Petcharopas
Alin Petcharopas
SWSupreeya Wongtra-Ngan
Supreeya Wongtra-Ngan
OCOrawee Chinthakanan
Orawee Chinthakanan

9 November 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
AKAthasit Kijmanawat
Athasit Kijmanawat
ASApisith Saraluck
Apisith Saraluck
JMJittima Manonai
Jittima Manonai
RWRujira Wattanayingcharoenchai
Rujira Wattanayingcharoenchai
KAKomkrit Aimjirakul
Komkrit Aimjirakul
OCOrawee Chinthakanan
Orawee Chinthakanan
A first-line treatment for stress urinary incontinence (SUI) is pelvic floor muscle training (PFMT) for at least three months. The key problem is that patients do not understand the importance of these exercises and their effectiveness. Mobile health apps offer new possibilities to increase treatment adherence. This study compared a reduction in SUI, exercise adherence, and quality of life in PFMT with animation vs. standard instruction. A prospective, single-blind, randomized control trial was collected. SUI patients were randomized into the application or control groups confirmed using a one-hour pad test. In the intervention group, the PFMT application was applied via mobile phone (PFMT with animations, recording system, and reminder system). The standard exercise protocol was similar in both groups. Additional follow-up was conducted at 4, 8, and 12 weeks. A total of 51 participants were randomized to the application (n = 26) and control groups (n = 25), respectively. At the 12-week follow-up, there was no significant difference between the two groups in terms of SUI cure rate, SUI severity by pad test, and daily SUI episodes from the bladder diary (p-value of 0.695, 0.472, and 0.338, respectively). The mean PFME adherence in the application group was higher than the control group at 8 weeks (66.3 ± 13.6 vs. 52.7 ± 16.6, p = 0.002) and 12 weeks (59.1 ± 13.9 vs. 37.8 ± 11.0, p = 0.001). The application group reported no difference from the conventional PFMT group in terms of improvements in SUI cure rate, symptom severity, and quality of life effects at 12-week follow-up. However, the improvement evaluated by the mean difference in SUI episodes and quality of life effects (ICIQ-UI SF) reported a better outcome in the mobile app group. The PFMT application has been proven to be an effective tool that improves PFMT adherence.